OSR Health (OSRHW) Cash from Financing Activities (2022 - 2026)
OSR Health (OSRHW) posted Cash from Financing Activities of $942101.7 for Q1 2026, down 70.67% sequentially from $3.2 million in Q4 2025, and up 530.67% YoY from $149381.1 in Q1 2025.
OSR Health (OSRHW) Cash from Financing Activities (2022 - 2026) Analysis & Trends
OSR Health has reported Cash from Financing Activities for 5 years, with the latest figure at $942101.7 in Q1 2026.
- Quarterly Cash from Financing Activities rose 530.67% year-over-year to $942101.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 million (up 758.46% YoY) and the FY2025 annual result came in at $8.4 million, up 606.57% from the prior year.
- Cash from Financing Activities declined to $942101.7 in Q1 2026 per OSRHW's latest filing, from $3.2 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $70.5 million in Q1 2023 and troughed at -$36.1 million in Q4 2023.
- A 5-year average of $3.0 million and a median of $266582.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 2290.82% in 2023, down 63932.58% in 2023.
- Over 5 years, Cash from Financing Activities stood at $56618.0 in 2022, then slumped by 63932.58% to -$36.1 million in 2023, then surged by 100.89% to $321516.0 in 2024, then surged by 898.89% to $3.2 million in 2025, then tumbled by 70.67% to $942101.7 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $942101.7, $3.2 million, and $4.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | -273.15 Mn |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn | 27.18 Mn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | 2.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 942,101.71 |
| Mar 31, 2026 | 942,101.71 |
| Dec 31, 2025 | 3.21 Mn |
| Dec 31, 2025 | 3.21 Mn |
| Sep 30, 2025 | 4.12 Mn |
| Sep 30, 2025 | 4.12 Mn |
| Jun 30, 2025 | 891,481.86 |
| Jun 30, 2025 | 891,481.86 |
| Mar 31, 2025 | 149,381.14 |
| Mar 31, 2025 | 149,381.14 |
| Dec 31, 2024 | 321,516.00 |
| Dec 31, 2024 | 321,516.00 |
| Sep 30, 2024 | 337,970.00 |
| Sep 30, 2024 | 337,970.00 |
| Jun 30, 2024 | 258,266.00 |
| Jun 30, 2024 | 258,266.00 |
| Mar 31, 2024 | 266,582.00 |
| Mar 31, 2024 | 266,582.00 |
| Dec 31, 2023 | -36.14 Mn |
| Dec 31, 2023 | -36.14 Mn |